Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow Quality Index
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow Quality Index of 4.85x as of September 2025. Operating cash flow of CN¥11.57 Million exceeds net income of CN¥2.39 Million, indicating high earnings quality where cash backs reported profits. Explore cash flow conversion of Hubei Biocause Heilen Pharmaceutical Co. to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 301211 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
Year-by-year earnings quality comparison for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. For live market cap and the full company financial profile, see market cap of Hubei Biocause Heilen Pharmaceutical Co..
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥7.55 Million | CN¥34.91 Million | ▼ -79.4% |
| 2024 | 1.05x | CN¥96.07 Million | CN¥91.55 Million | ▲ +34.8% |
| 2023 | 0.78x | CN¥137.06 Million | CN¥176.12 Million | ▼ -61.0% |
| 2022 | 1.99x | CN¥250.79 Million | CN¥125.72 Million | ▲ +95.7% |
| 2021 | 1.02x | CN¥123.98 Million | CN¥121.65 Million | ▲ +40.8% |
| 2020 | 0.72x | CN¥121.67 Million | CN¥168.07 Million | ▼ -64.1% |
| 2019 | 2.02x | CN¥372.33 Million | CN¥184.62 Million | ▲ +142.2% |
| 2018 | 0.83x | CN¥76.18 Million | CN¥91.48 Million | ▲ +130.3% |
| 2017 | -2.75x | CN¥-65.44 Million | CN¥23.77 Million | — |